Mesotherapy Treatment of Irritable Bowel Syndrome
Key facts
- Who runs it
- Polyclinique de l'Europe
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2
- People taking part
- 27 people enrolled
- Started
- 28 Feb 2024
- Expected to end
- 31 Jan 2027
- Type of study
- Interventional
- Treatments tested
- Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate
- Record updated
- 31 May 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Patient suffering from Irritable Bowel Syndrome according to the Rome IV criteria, whose diagnosis was made by a specialist in Hepato-Gastro-Enterology,
- Francis score >75/500, i.e. minimal, moderate or severe severity,
- Patient who has failed conventional treatment (treatment followed for at least 1 year and not showing an improvement in symptoms)
- Absence of risk of ongoing pregnancy in women of childbearing age, validated by a urine test during the first consultation and before treatment and each month during treatment and until 1 month after the end of treatment
Who cannot take part
- Patient with the following medical history or current pathologies: organic gastrointestinal pathology, disabling neurological pathology, disabling psychiatric pathology
- Recent Post Traumatic Stress Syndrome (<1 year),
- Fibromyalgia syndrome,
- Known allergy to medications used in mesotherapy treatment,
- Pregnant or breastfeeding woman
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Irritable bowel syndrome (IBS) is a gastrointestinal transit disorder characterized by chronic abdominal pain and impaired transit in the absence of demonstrated organic disease. Considered a non-fatal disease, its effects relate more to quality of life, work production and health care systems.
Read full original descriptionShow less
Given the complexity of this disease, no treatment has been recognized as standard treatment. The treatment is rather focused on treating the symptoms caused (chronic pain or intestinal transit disorder). In general, therapy is considered individualized and includes lifestyle/diet modifications and pharmaceutical therapy.
Several published case studies evaluating the effect of mesotherapy on improving the severity of the disease have demonstrated an improvement in the symptoms of this syndrome. Due to the limited number of case studies and the insufficient level of evidence to conclude, our study will therefore be a before-and-after intervention study, to evaluate the effect of four mesotherapy sessions on the treatment of IBS symptoms.
The group in the trial
- Experimental groupTreatment being tested
Treatment: Mesotherapy with mesocaine, thiocolchicoside, amitriptyline, magnesium pidolate
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 31 May 2025